BioAge Labs, Inc. (BIOA)
NASDAQ: BIOA · Real-Time Price · USD
19.60
+1.33 (7.28%)
At close: Jan 27, 2026, 4:00 PM EST
20.09
+0.49 (2.50%)
After-hours: Jan 27, 2026, 6:51 PM EST
BioAge Labs Employees
As of December 31, 2024, BioAge Labs had 64 total employees, including 62 full-time and 2 part-time employees. The number of employees increased by 8 or 14.29% compared to the previous year.
Employees
64
Change
8
Growth
14.29%
Revenue / Employee
$92,453
Profits / Employee
-$1,184,234
Market Cap
818.35M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 64 | 8 | 14.29% | 62 | 2 |
| Jun 30, 2024 | 60 | - | - | 58 | 2 |
| Mar 31, 2024 | 56 | - | - | 54 | 2 |
| Dec 31, 2023 | 56 | - | - | 54 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Tilray Brands | 2,842 |
| Amphastar Pharmaceuticals | 2,028 |
| Emergent BioSolutions | 900 |
| Organogenesis Holdings | 869 |
| Pacira BioSciences | 790 |
| Cronos Group | 459 |
| Kamada | 420 |
| Esperion Therapeutics | 304 |
BIOA News
- 6 days ago - BioAge Announces Pricing of Upsized $115.0 Million Public Offering - GlobeNewsWire
- 7 days ago - BioAge Announces Proposed Public Offering - GlobeNewsWire
- 7 days ago - BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 - GlobeNewsWire
- 15 days ago - BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk - GlobeNewsWire
- 7 weeks ago - BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor - GlobeNewsWire
- 2 months ago - BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - BioAge Labs to Present at Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 4 months ago - HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor - PRNewsWire